Literature DB >> 26080355

Studying the binding interactions of allosteric agonists and antagonists of the CXCR4 receptor.

Jesús M Planesas1, Violeta I Pérez-Nueno2, José I Borrell1, Jordi Teixidó3.   

Abstract

Several examples of allosteric modulators of GPCRs have been reported recently in the literature, but understanding their molecular mechanism presents a new challenge for medicinal chemistry. For the specific case of the cellular receptor CXCR4, it is known that pepducins (lipidated fragments of intracellular GPCR loops) such as ATI-2341 modulate CXCR4 activity agonistically via an allosteric mechanism. Moreover, there are also examples of small organic molecules such as AMD11070 and GSK812397 which may also act as allosteric antagonists. However, incomplete knowledge of the ligand-binding sites has hampered a detailed molecular understanding of how these inhibitors work. Here, we attempt to answer this question by analysing the binding interactions between the CXCR4 receptor and the above-mentioned allosteric modulators. We propose two different allosteric binding sites, one located in the intracellular loops 1, 2 and 3 (ICL1, ICL2 and ICL3) which binds the pepducin agonist ATI-2341, and the other at a subsite of the main extracellular orthosteric binding pocket between extracellular loops 1 and 2 and the N-terminus, which binds the antagonists AMD11070 and GSK812397. Allosteric interactions between the CXCR4 and ATI-2341 were predicted by combining different modeling approaches. First, a rotational blind docking search was applied and the best poses were subsequently refined using flexible docking methods and molecular dynamic simulations. For the AMD11070 and GSK812397 antagonists, the entire CXCR4 protein surface was explored by blind docking in order to define the binding region. A second docking analysis by subsites was then performed to refine the allosteric interactions. Finally, we identified the binding residues that appear to be essential for CXCR4 allosteric modulators.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Allosteric agonists and antagonists; Allosteric binding sites; CXCR4; Docking

Mesh:

Substances:

Year:  2015        PMID: 26080355     DOI: 10.1016/j.jmgm.2015.05.004

Source DB:  PubMed          Journal:  J Mol Graph Model        ISSN: 1093-3263            Impact factor:   2.518


  4 in total

1.  Pharmacophore modeling, atom based 3D-QSAR and Molecular docking approaches to screen C-X-C chemokine receptor type 4 antagonists as microbicides for human immunodeficiency virus-1.

Authors:  Radhika Ramachandran; Shanmughavel Piramanyagam
Journal:  Virusdisease       Date:  2017-09-26

Review 2.  Targeting CXCL12/CXCR4 Axis in Tumor Immunotherapy.

Authors:  Weiqiang Zhou; Shanchun Guo; Mingli Liu; Matthew E Burow; Guangdi Wang
Journal:  Curr Med Chem       Date:  2019       Impact factor: 4.530

3.  Discovery of novel aminopiperidinyl amide CXCR4 modulators through virtual screening and rational drug design.

Authors:  Yoon Hyeun Oum; Steven A Kell; Younghyoun Yoon; Zhongxing Liang; Pieter Burger; Hyunsuk Shim
Journal:  Eur J Med Chem       Date:  2020-06-06       Impact factor: 6.514

Review 4.  CXCL12 Signaling in the Tumor Microenvironment.

Authors:  Luigi Portella; Anna Maria Bello; Stefania Scala
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.